EA202090909A1 - Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство - Google Patents

Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство

Info

Publication number
EA202090909A1
EA202090909A1 EA202090909A EA202090909A EA202090909A1 EA 202090909 A1 EA202090909 A1 EA 202090909A1 EA 202090909 A EA202090909 A EA 202090909A EA 202090909 A EA202090909 A EA 202090909A EA 202090909 A1 EA202090909 A1 EA 202090909A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
therapy
ways
side effects
reduce side
Prior art date
Application number
EA202090909A
Other languages
English (en)
Inventor
Томас Мэнли
Нил Джозефсон
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2018/055354 external-priority patent/WO2019075168A2/en
Publication of EA202090909A1 publication Critical patent/EA202090909A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное описание относится в целом к способам ослабления нежелательных явлений у субъектов, получающих лечение конъюгатом анти-CD30 антитело-лекарственное средство, необязательно также получающих сопутствующую химиотерапию. Нежелательные явления включают периферическую нейропатию и нейтропению.
EA202090909A 2018-08-16 2018-10-11 Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство EA202090909A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764805P 2018-08-16 2018-08-16
PCT/US2018/055354 WO2019075168A2 (en) 2017-10-11 2018-10-11 METHODS OF REDUCING SIDE EFFECTS OF DRUG-CONJUGATED DRUG THERAPY ANTI-CD30

Publications (1)

Publication Number Publication Date
EA202090909A1 true EA202090909A1 (ru) 2020-08-24

Family

ID=72235070

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090909A EA202090909A1 (ru) 2018-08-16 2018-10-11 Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство

Country Status (1)

Country Link
EA (1) EA202090909A1 (ru)

Similar Documents

Publication Publication Date Title
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
EA202190403A1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PH12020551726A1 (en) Treatment of atopic dermatitis
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA202190862A1 (ru) Способы лечения
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2020004563A (es) Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202090909A1 (ru) Способы уменьшения побочных эффектов терапии конъюгатом анти-cd30 антитело-лекарственное средство
WO2019075168A3 (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
ZA202201446B (en) Methods of treating multifocal cancer
EA202091087A1 (ru) Способы ослабления побочных эффектов терапии конъюгатом "антитело против cd30-лекарственное средство"
EA202191273A1 (ru) Применение тивозаниба для лечения субъектов с рефрактерным раком
EA202091802A1 (ru) Производные бексаротена и их применения для лечения рака
AR113554A1 (es) Métodos de reducción de efectos secundarios del tratamiento con conjugado de anticuerpo anti-cd30-fármaco